ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
-0,01%
Bitcoin
66.844,99
-0,35%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Xeris Biopharma Holdings Inc (XERS)

  7. Xeris Biopharma Holdings Inc (XERS) News

XERS

Xeris Biopharma (XERS)

Xeris Biopharma Holdings Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:XERS
DatumZeitQuelleÜberschriftSymbolFirma
09/05/202413h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
09/05/202413h00Business WireXeris Biopharma Reports First Quarter 2024 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/05/202413h00Business WireXeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta BionicsNASDAQ:XERSXeris Biopharma Holdings Inc
02/05/202413h00Business WireXeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
03/04/202422h05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
02/04/202413h00Business WireXeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202422h19Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202422h10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413h02Business WireXeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent EventsNASDAQ:XERSXeris Biopharma Holdings Inc
06/03/202413h00Business WireXeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin CapitalNASDAQ:XERSXeris Biopharma Holdings Inc
28/02/202413h00Business WireXeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024NASDAQ:XERSXeris Biopharma Holdings Inc
05/02/202413h00Business WireXeris to Present at the Oppenheimer 34th Annual Healthcare Life Science ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
31/01/202423h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202416h12Dow Jones NewsXeris Biopharma Shares Climb 12% on Amgen License AgreementNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202414h53Dow Jones NewsXeris Biopharma Reaches License Agreement With Amgen On Thyroid Eye Disease TreatmentNASDAQ:XERSXeris Biopharma Holdings Inc
10/01/202414h00Business WireXeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of TeprotumumabNASDAQ:XERSXeris Biopharma Holdings Inc
05/01/202422h05Business WireXeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:XERSXeris Biopharma Holdings Inc
04/01/202413h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
04/01/202413h00Business WireXeris Biopharma Updates Its Outlook for 2023NASDAQ:XERSXeris Biopharma Holdings Inc
27/12/202313h00Business WireXeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:XERSXeris Biopharma Holdings Inc
21/11/202322h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XERSXeris Biopharma Holdings Inc
09/11/202322h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XERSXeris Biopharma Holdings Inc
09/11/202313h20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
09/11/202313h00Business WireXeris Biopharma Reports Third Quarter 2023 Financial ResultsNASDAQ:XERSXeris Biopharma Holdings Inc
16/10/202313h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
16/10/202313h00Business WireXeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023NASDAQ:XERSXeris Biopharma Holdings Inc
29/09/202322h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
27/09/202314h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XERSXeris Biopharma Holdings Inc
27/09/202314h00Business WireXeris Biopharma Announces Private Convertible Note Exchange TransactionsNASDAQ:XERSXeris Biopharma Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:XERS

Kürzlich von Ihnen besucht

NASDAQ
ABAYGXX
Morgan Stanley Finance L...
LSE
NWN
Newmarket Investments
ASX
MQGMOR
ASX
AAM
A1 Minerals
BIT
UV8CPE
UniCredit Bank
KUCN
UQCETH
Uquid Coin
AMEX
CNR
Canargo
COIN
CUTTEUR
COIN
GFCUSD
TG
ETE
Ekotechnika
LSE
51TU
Qnb Fin 23
BIT
1FISV
Fiserv Inc Dl 01
ASX
PGD
Peregrine Gold
COIN
SDASHBTC
XE
S3CH
Leverage Shares Public
NASDAQ
ZAARGX
Aberdeen Venture Partner...
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten